These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16951335)

  • 1. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells.
    Taylor GS; Long HM; Haigh TA; Larsen M; Brooks J; Rickinson AB
    J Immunol; 2006 Sep; 177(6):3746-56. PubMed ID: 16951335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
    Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB
    Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
    Long HM; Haigh TA; Gudgeon NH; Leen AM; Tsang CW; Brooks J; Landais E; Houssaint E; Lee SP; Rickinson AB; Taylor GS
    J Virol; 2005 Apr; 79(8):4896-907. PubMed ID: 15795275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigens and autophagy: the path less travelled?
    Taylor GS; Rickinson AB
    Autophagy; 2007; 3(1):60-2. PubMed ID: 17102586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.
    Voo KS; Fu T; Heslop HE; Brenner MK; Rooney CM; Wang RF
    Cancer Res; 2002 Dec; 62(24):7195-9. PubMed ID: 12499257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.
    Leung CS; Haigh TA; Mackay LK; Rickinson AB; Taylor GS
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2165-70. PubMed ID: 20133861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.
    Long HM; Zuo J; Leese AM; Gudgeon NH; Jia H; Taylor GS; Rickinson AB
    Blood; 2009 Jul; 114(4):807-15. PubMed ID: 19443664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.
    Destro F; Sforza F; Sicurella M; Marescotti D; Gallerani E; Baldisserotto A; Marastoni M; Gavioli R
    Immunology; 2011 May; 133(1):105-14. PubMed ID: 21342184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
    Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
    Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design.
    Thomson SA; Burrows SR; Misko IS; Moss DJ; Coupar BE; Khanna R
    J Virol; 1998 Mar; 72(3):2246-52. PubMed ID: 9499082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
    Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
    Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
    J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.
    Long HM; Leese AM; Chagoury OL; Connerty SR; Quarcoopome J; Quinn LL; Shannon-Lowe C; Rickinson AB
    J Immunol; 2011 Jul; 187(1):92-101. PubMed ID: 21622860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.
    Blake N; Haigh T; Shaka'a G; Croom-Carter D; Rickinson A
    J Immunol; 2000 Dec; 165(12):7078-87. PubMed ID: 11120837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.